Good morning, everyone, and how are you today? We are doing just fine, thank you, despite the gloomy skies hovering overhead. After all, as the Morning Mayor used to say, “Every brand new day should be unwrapped like a precious gift.” While you contemplate the possibilities and tug on the ribbon just a little, we will fire up the coffee kettle and make yet another cup of stimulation as we set about our journey. As always, you are welcome to join us. Meanwhile, here are a few items of interest to help you along. Hope you have a productive day and do keep in touch …

The European Medicines Agency updated its assessment of risk from valsartan medicines containing NDMA, a substance linked to cancer, after examining test results from supplies made by Zhejiang Huahai. The agency estimates the risk to be about 1 in 5,000 for an adult who had taken a medicine at the highest dose — 320 mg — every day from July 2012 to July 2018, which is line with previous calculations. To some extent, the estimate is supported by a Danish study that tracked patients who had taken medicines containing valsartan from Zhejiang Huahai over the past six years.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy